Myeloablative autologous hematopoietic stem cell transplantation (HSCT) is a mainstay of
therapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma (NHL); however …

Improvements in the quality and fitness of chimeric antigen receptor (CAR)-engineered T
cells, through CAR design or manufacturing optimizations, could enhance the therapeutic …

The success of adoptive therapy using chimeric antigen receptor (CAR)–expressing T cells
partly depends on optimal CAR design. CARs frequently incorporate a spacer/linker region …

Purpose: Multiple myeloma remains an incurable malignancy of plasma cells despite
considerable advances in treatment. The purpose of the study was to develop novel …

Advancing chimeric antigen receptor (CAR)-engineered adoptive T cells for the treatment of
solid cancers is a major focus in the field of immunotherapy, given impressive recent clinical …

Background Insufficient persistence and effector function of chimeric antigen receptor (CAR)-
redirected T cells have been challenging issues for adoptive T cell therapy. Generating …

Purpose: T cells engineered with chimeric antigen receptors (CAR) recognizing CD19 can
induce complete remission of B-cell malignancies in clinical trials; however, in some disease …

Lymphomas with central nervous system (CNS) involvement confer a worse prognosis than
those without CNS involvement, and patients currently have limited treatment options. T cells …

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator
(CFTR) gene. The majority of CFTR mutations result in impaired chloride channel function …

The adaptive T cell immune response requires cellular plasticity to generate distinct subsets
with diverse functional and migratory capacities. Studies of CAR T cells have primarily …